1. Home
  2. ARAY vs NYXH Comparison

ARAY vs NYXH Comparison

Compare ARAY & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accuray Incorporated

ARAY

Accuray Incorporated

HOLD

Current Price

$0.99

Market Cap

170.1M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.87

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARAY
NYXH
Founded
1990
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.1M
188.1M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
ARAY
NYXH
Price
$0.99
$4.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.50
$12.67
AVG Volume (30 Days)
1.2M
56.3K
Earning Date
11-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$450,902,000.00
$6,616,215.00
Revenue This Year
$3.82
$79.25
Revenue Next Year
$4.08
$297.08
P/E Ratio
N/A
N/A
Revenue Growth
1.51
10.96
52 Week Low
$0.91
$4.35
52 Week High
$2.95
$11.87

Technical Indicators

Market Signals
Indicator
ARAY
NYXH
Relative Strength Index (RSI) 32.66 48.96
Support Level $1.00 $4.60
Resistance Level $1.06 $5.01
Average True Range (ATR) 0.06 0.24
MACD 0.02 0.04
Stochastic Oscillator 34.85 83.33

Price Performance

Historical Comparison
ARAY
NYXH

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: